We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App




ELISA Kit Used to Measure Predictive Marker for Diabetic Kidney Disease

By LabMedica International staff writers
Posted on 16 Dec 2015
A recently concluded study confirmed the usefulness of using the protein sTNFR1 (soluble tumor necrosis factor receptor 1) as a biomarker to predict progression of diabetic nephropathy (also referred to as diabetic kidney disease).

Elevations in circulating soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and 2) have been reported in a wide variety of clinical conditions including cancer, congestive heart failure, rheumatoid arthritis, neurological diseases, and infection. More...
In addition, a study conducted at the Joslin Diabetes Center (Boston, MA, USA) has shown that elevated circulating sTNFR1 levels were associated with the subsequent development of advanced diabetic kidney disease in Type I and Type II diabetic patients. These findings were based on TNFR1 data on 1335 patients followed over a four to six year period.

During the study levels of sTNFR1 in serum or plasma were measured with the EKF Diagnostics (Cardiff, United Kingdom) Human sTNFR1 EIA kit. This is a 4.5 hour solid phase quantitative sandwich enzyme immunoassay. The test procedure is based on the sequential addition of sample, polyclonal anti-human sTNFR1 antibody-enzyme conjugate, and colorimetric substrate to microplate wells coated with anti-human sTNFR1 monoclonal antibody. The resultant color intensity is proportional to the concentration of sTNFR1 in the test sample. Test results are determined from a standard curve calibrated against a highly-purified E. coli-expressed recombinant human sTNFR1 protein corresponding to the N-terminal ectodomain.

The Joslin Diabetes Center study was presented at "Kidney Week," the November 3–8, 2015, annual meeting of the American Society for Nephrology held in San Diego (CA, USA).

Related Links:

Joslin Diabetes Center
EKF Diagnostics 



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.